Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 3/2024

11-01-2024 | Peripheral Nervous System Disease

Vasculitic Neuropathies

Authors: Avi Landman, MD, Mark Levine, MD, Andrés M. De León, MD

Published in: Current Treatment Options in Neurology | Issue 3/2024

Login to get access

Abstract

Purpose of review

To describe the clinical presentation, diagnosis, and treatment options of vasculitic neuropathies. Overall, vasculitic neuropathies can be divided into systemic and nonsystemic. Systemic vasculitic neuropathies form part of rheumatological diseases, where in some cases, the vasculitic is the predominant feature, and these are called primary vasculitis, while in others, the vasculitis is secondary to a connective tissue disease. Nonsystemic vasculitic neuropathies involve only the peripheral nervous system, and thus, diagnosis is more challenging as it requires a high degree of suspicion and confirmation with nerve biopsy results.

Recent findings

Over the past few years, rituximab has been increasingly used for induction and maintenance treatment of vasculitis due to a more favorable side effect profile and similar efficacy when compared to cyclophosphamide.

Summary

Herein, we describe the different types of vasculitic neuropathies. Regarding their treatment, have focused on the indications, dosing, and side effects for the most common options for primary systemic vasculitic neuropathies, as these tend to be similar for the classical nonsystemic vasculitic neuropathy phenotype.
Literature
1.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.PubMedCrossRef
2.
3.
•• Gwathmey KG, Burns TM, Collins MP, Dyck PJB. Vasculitic neuropathies. Lancet Neurol. 2014;13:67–82. In-depth review of the clinical presentation and pathology findings of systemic and non-systemic vasculitic neuropathies.
4.
Collins MP, Dyck PJB, Gronseth GS, et al. Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15:176–84.PubMedCrossRef
5.
Amato AA, Russell JA. Neuromuscular disorders. 2nd ed. United Kingdom: McGraw-Hill Education; 2015.
6.
7.
8.
9.
Nathani D, Barnett MH, Spies J, Pollard J, Wang M, Kiernan MC. Vasculitic neuropathy: comparison of clinical predictors with histopathological outcome. Muscle Nerve. 2019;59:643–9.PubMedCrossRef
10.
11.
Vrancken AFJE, Gathier CS, Cats EA, Notermans NC, Collins MP. The additional yield of combined nerve/muscle biopsy in vasculitic neuropathy. Eur J Neurol. 2011;18:49–58.PubMedCrossRef
12.
• Dyck PJ, Benstead TJ, Conn DL, Stevens JC, Windebank AJ, Low PA. Nonsystemic vasculitic neuropathy. Brain. 1987;110:843–53. One of the first case series of non-systemic vasculitic neuropathies. 
13.
Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13:1121–5.PubMedCrossRef
14.
Stone JH, Group WGETR. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum. 2003;48:2299–309.CrossRef
15.
Holle JU, Gross WL. Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol. 2011;23:7–11.PubMedCrossRef
16.
Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42:421–30.PubMedCrossRef
17.
Hattori N, Mori K, Misu K, Koike H, Ichimura M, Sobue G. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol. 2002;29:1408–14.PubMed
18.
Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65:270–81.PubMedCrossRef
19.
Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Guern VL, Bienvenu B, Mouthon L, Guillevin L, Group FVS. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62:616–26.CrossRef
20.
Tulbă D, Popescu BO, Manole E, Băicuș C. Immune axonal neuropathies associated with systemic autoimmune rheumatic diseases. Front Pharmacol. 2021;12:610585.PubMedPubMedCentralCrossRef
21.
22.
Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Rheumatol. 2021;73:1384–93.PubMedCrossRef
23.
•• Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ. 2020;368:m421. Recent review detailing the evidence for treatment of AAV. 
24.
Chevet B, Cornec D, Moura MC, Gall EC-L, Fervenza FC, Warrington KJ, Specks U, Berti A. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology. 2022;62:1787–803.CrossRef
25.
26.
Fauci AS, Wolff SM. Wegener’s granulomatosis: studies in eighteen patients and a revision of the literature. Medicine. 1974;52:535–61.CrossRef
27.
Naddaf E, Dyck PJB. Vasculitic neuropathies. Curr Treat Options Neurol. 2015;17:44.CrossRef
28.
Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955.PubMedCrossRef
29.
30.
van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmattulla C. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064.PubMedCrossRef
31.
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRef
32.
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.PubMedCrossRef
33.
Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–803.PubMedCrossRef
34.
Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41:203–11.PubMedCrossRef
35.
Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71:84.PubMedCrossRef
36.
Vrancken AF, Hughes RA, Said G, Wokke JH, Notermans NC. Immunosuppressive treatment for non‐systemic vasculitic neuropathy. Cochrane Database Syst Rev. 2007;CD006050.
37.
Mathew L, Talbot K, Love S, Puvanarajah S, Donaghy M. Treatment of vasculitic peripheral neuropathy: A retrospective analysis of outcome. QJM Int J Med. 2007;100:41–51.
38.
Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61:623–30.PubMedCrossRef
39.
Üçeyler N, Geng A, Reiners K, Toyka KV, Sommer C. Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol. 2015;262:2092–100.PubMedCrossRef
40.
Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain. 1996;119:1441–8.PubMedCrossRef
41.
Staff NP, Engelstad J, Klein CJ, Amrami KK, Spinner RJ, Dyck PJ, Warner MA, Warner ME, Dyck PJB. Post-surgical inflammatory neuropathy. Brain. 2010;133:2866–80.PubMedCrossRef
42.
Rattananan W, Thaisetthawatkul P, Dyck PJB. Postsurgical inflammatory neuropathy: a report of five cases. J Neurol Sci. 2014;337:137–40.PubMedCrossRef
43.
van Alfen N, van Engelen BGM. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2006;129:438–50.PubMedCrossRef
44.
Gstoettner C, Mayer JA, Rassam S, Hruby LA, Salminger S, Sturma A, Aman M, Harhaus L, Platzgummer H, Aszmann OC. Neuralgic amyotrophy: a paradigm shift in diagnosis and treatment. J Neurol, Neurosurg Psychiatry. 2020;91:879–88.PubMedCrossRef
45.
Suarez GA, Giannini C, Bosch EP, Barohn RJ, Wodak J, Ebeling P, Anderson R, McKeever PE, Bromberg MB, Dyck PJ. Immune brachial plexus neuropathy: suggestive evidence for an inflammatory-immune pathogenesis. Neurology. 1996;46:559–61.PubMedCrossRef
46.
van Eijk JJJ, van Alfen N, Berrevoets M, van der Wilt GJ, Pillen S, van Engelen BGM. Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. J Neurol, Neurosurg Psychiatry. 2009;80:1120.PubMedCrossRef
47.
Janssen RMJ, Lustenhouwer R, Cup EHC, et al. Effectiveness of an outpatient rehabilitation programme in patients with neuralgic amyotrophy and scapular dyskinesia: a randomised controlled trial. J Neurol, Neurosurg Psychiatry. 2023;94:474–81.PubMedCrossRef
48.
Sneag DB, Urban C, Li TY, Colucci PG, Pedrick EG, Nimura CA, Feinberg JH, Milani CJ, Tan ET. Hourglass-like constrictions on MRI are common in electromyography-confirmed cases of neuralgic amyotrophy (Parsonage–Turner syndrome): a tertiary referral center experience. Muscle Nerve. 2023. https://​doi.​org/​10.​1002/​mus.​27961.CrossRefPubMed
49.
Ripellino P, Arányi Z, Alfen N, Ventura E, Peyer A, Cianfoni A, Gobbi C, Pedrick E, Sneag DB. Imaging of neuralgic amyotrophy in the acute phase. Muscle Nerve. 2022;66:709–14.PubMedCrossRef
50.
ArÁnyi Z, Csillik A, DéVay K, Rosero M, Barsi P, BÖhm J, Schelle T,. Ultrasonography in neuralgic amyotrophy: sensitivity, spectrum of findings, and clinical correlations. Muscle nerve. 2017;56:1054–62.PubMedCrossRef
51.
Pinto MV, Ng P, Laughlin RS, Thapa P, Pinto CA, Shelly S, Shouman K, Dyck PJ, Dyck PJB. Risk factors for lumbosacral radiculoplexus neuropathy. Muscle Nerve. 2022;65:593–8.PubMedPubMedCentralCrossRef
52.
Garces-Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJB. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus Neuropathy? Ann Neurol. 2011;69:1043–54.PubMedPubMedCentralCrossRef
53.
Hlis R, Poh F, Bryarly M, Xi Y, Chhabra A. Quantitative assessment of diabetic amyotrophy using magnetic resonance neurography—a case-control analysis. Eur Radiol. 2019;29:5910–9.PubMedCrossRef
54.
Llewelyn JG, Thomas PK, King RHM. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol. 1998;245:159–65.PubMedCrossRef
55.
Massie R, Mauermann ML, Staff NP, Amrami KK, Mandrekar JN, Dyck PJ, Klein CJ, Dyck PJB. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain. 2012;135:3074–88.PubMedCrossRef
56.
Said G, Lacroix C, Lozeron P, Ropert A, Planté V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain. 2003;126:376–85.PubMedCrossRef
57.
Dyck PJB, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 1999;53:2113–21.PubMedCrossRef
58.
Eijk J van, Chan YC, Russell JW. Immunotherapy for idiopathic lumbosacral plexopathy. Cochrane Database Syst Rev. 2014;CD009722.
59.
Dyck PJB, Norell JE, Dyck PJ. Methylprednisolone may improve lumbosacral radiculoplexus neuropathy. Can J Neurol Sci. 2001;28:224–7.PubMedCrossRef
60.
Dyck P, P O, EP B, et al. The multi-center double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 2006;66:A191.
61.
Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med. 2009;10:1476–80.PubMedCrossRef
62.
Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y. Infection and vasculitis. Rheumatology. 2009;48:475–82.PubMedCrossRef
63.
DeLeón AM, Garcia-Santibanez R, Harrison TB. Article topic: neuropathies due to infections and antimicrobial treatments. Curr Treat Options Neurol. 2023;25:213–29.CrossRef
64.
65.
Vita SD, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.PubMedCrossRef
66.
Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts. Liver Int. 2020;40:1841–52.PubMedPubMedCentralCrossRef
67.
Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C. Cryoglobulinaemia. Nat Rev Dis Prim. 2018;4:11.PubMedCrossRef
68.
Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus–related polyarteritis nodosa. Arthritis Care Res. 2004;51:482–7.CrossRef
Metadata
Title
Vasculitic Neuropathies
Authors
Avi Landman, MD
Mark Levine, MD
Andrés M. De León, MD
Publication date
11-01-2024
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 3/2024
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-024-00782-x
Image Credits